Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial
European Journal of Cancer · 2026-06 · 240 · 116730
DOI: 10.1016/j.ejca.2026.116730 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2026-06. Verfasst von Bertrand Tombal und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Urology, IREC, Cliniques Universitaires Saint Luc, UCLouvain, Brussels, Belgium. Electronic address: bertrand.tombal@saintluc.uclouvain.b…. Hauptthemen laut MEDLINE: Docetaxel, Antineoplastic Combined Chemotherapy Protocols, Prostatic Neoplasms, Androgen Antagonists. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bayer HealthCare Pharmaceuticals Inc, Bayer HealthCare.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Urology, IREC, Cliniques Universitaires Saint Luc, UCLouvain, Brussels, Belgium. Electronic address: bertrand.tombal@saintluc.uclouvain.be.
- Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.
- University of Montreal Hospital Center, Montreal, Quebec, Canada.
- Centre Oscar Lambret, Institut Gustave Roussy, University of Paris-Saclay, Lille, France.
- START Carolinas/Carolina Urologic Research Center, Myrtle Beach, SC, USA.
- Clinical Oncological Dispensary of Omsk Region, Omsk, Russian Federation.
Förderung
- Bayer HealthCare Pharmaceuticals Inc
- Bayer HealthCare
Zitieren
APA
Tombal, B., Hussain, M., Saad, F., Fizazi, K., Shore, N., Kopyltsov, E., Bögemann, M., Mendez-Vidal, M. J., Littleton, N., Srinivasan, S., Verholen, F., & Smith, M. R. (2026). Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial. European Journal of Cancer, 240, 116730. https://doi.org/10.1016/j.ejca.2026.116730
Vancouver
Tombal B, Hussain M, Saad F, Fizazi K, Shore N, Kopyltsov E, et al. Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial. European Journal of Cancer. 2026;240:116730. doi:10.1016/j.ejca.2026.116730
BibTeX
@article{Tombal2026,
author = {Tombal, Bertrand and Hussain, Maha and Saad, Fred and Fizazi, Karim and Shore, Neal and Kopyltsov, Evgeny and Bögemann, Martin and Mendez-Vidal, Maria J and Littleton, Natasha and Srinivasan, Shankar and Verholen, Frank and Smith, Matthew R},
title = {Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial},
journal = {European Journal of Cancer},
year = {2026},
volume = {240},
pages = {116730},
doi = {10.1016/j.ejca.2026.116730}
}
EUVIMED